Cargando…
Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
BACKGROUND: This paper describes a Phase 1, single-center, randomized, open-label, two-period crossover study which compared the pharmacodynamic effects of single doses of dexlansoprazole modified-release 60 mg and esomeprazole 40 mg on 24-hour intragastric pH in healthy adult subjects. METHODS: For...
Autores principales: | Kukulka, Michael, Eisenberg, Corey, Nudurupati, Sai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190289/ https://www.ncbi.nlm.nih.gov/pubmed/22016582 http://dx.doi.org/10.2147/CEG.S24063 |
Ejemplares similares
-
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016) -
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
por: Kukulka, Michael, et al.
Publicado: (2017) -
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe
por: Kukulka, Michael, et al.
Publicado: (2018) -
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023) -
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)